Optimising hypertension treatment: NICE/BHS guideline implementation and audit for best practice

British Journal of Cardiology

Volumn 20, Issue SUPPL.1, 2013, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; POTASSIUM; SPIRONOLACTONE;

AGE DISTRIBUTION; ANTIHYPERTENSIVE THERAPY; ARTICLE; AUSCULTATION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE METER; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BRACHIAL ARTERY; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; DIURETIC THERAPY; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; PERIODIC MEDICAL EXAMINATION; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; UNITED KINGDOM;

EID: 84876548752     PISSN: 09696113     EISSN: None     Source Type: Journal    
DOI: 10.5837/bjc.2013.s01     Document Type: Article

References (34)

1. National Clinical Guideline Centre (NCGC). Hypertension: the clinical management of primary hypertension in adults. Clinical Guideline 127. Methods, evidence and recommendations. August 2011. Commissioned by the National Institute for Health and Clinical Excellence. London: NCGC, 2011. Available at http://www.nice.org.uk/nicemedia/live/13561/56007/56007.pdf (accessed 1 December 2012).
2. National Statistics. Health Service for England 2010-trend tables. NHS Information Centre 2011. Available at http://www.ic.nhs.uk/statistics-and-data- collections/health-and-lifestyles-related-surveys/health-survey-for-england/ health-survey-for-england-2010-trend-tables (accessed 1 December 2012).
3. Williams B. Hypertension and "J-curve". J Am Coll Cardiol 2009;54:1835-6. http://dx.doi.org/10.1016/j.jacc.2009.06.043
4. MeRec Bulletin. The management of hypertension in primary care: updated guidance from NICE. MeRec Bulletin 2006;17(1 part 2).
5. North of England Hypertension Guideline Development Group. Essential hypertension: managing adults in primary care. Clinical Guideline 18. Newcastle: August 2004. Available at http://www.guidance.nice.org/uk/CG18 (accessed 24 January 2013).
6. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians, 2006. Available at http://www.nice.org.uk/ nicemedia/pdf/CG34fullguideline.pdf (accessed 3 December 2012).
7. National Institute for Health and Clinical Excellence (NICE). How NICE clinical guidelines are developed: an overview for stakeholders, the public and the NHS (4th edition). January 2009. London: NICE, 2009. Available at http://www.nice.org.uk/media/62F/36/How-NICE-clinical-guidelines-are- developed-4th-edn-FIANL-LR.pdf (accessed 1 December 2012).
8. Laine C, Taichman DB, Mulrow C. Trustworthy clinical guidelines. Ann Intern Med 2011;154:774-5.
9. Oparil S (chair of JNC8) speaking at the European Society of Hypertension Annual Scientifc Meeting, London, 2012.
10. Lovibond K, Jowett S, Barton P, et al. Cost-effectiveness of options for the diagnosis of high blood pressure in primary care: a modelling study. Lancet 2011; 378:1219-30. http://dx.doi.org/10.1016/S0140-6736(11)61184-7
11. Gustavsen PH, Hoegholm A, Bang LE, Kristensen KS. White coat hypertension is a cardiovascular risk factor: a 10-year follow-up study. J Hum Hypertens 2003;17: 811-17. http://dx.doi.org/10.1038/sj.jhh.1001643 (Pubitemid 38028637)
12. National Institute for Health and Clinical Excellence. Lipid modifcation: cardiovascular risk assessment and the modifcation of blood lipids for the primary and secondary prevention of cardiovascular disease. May 2008 (reissued March 2010). London: NICE, 2008. Available at http://www.nice.org.uk/CG67 (accessed 1 December 2012).
13. Spinar J, Vitovec J, Soucek M, Dusek L, Pavlik T, Investigators CORD. CORD: COmparison of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers. Vnitrni Lekarstvi 2009;55(5):481-8.
14. Tedesco MA, Natale F, Calabro R. Effects of monotherapy and combination therapy on blood pressure control and target organ damage: a randomized prospective intervention study in a large population of hypertensive patients. J Clin Hypertens 2006;8(9):634-41. http://dx.doi.org/10.1111/j.1524-6175.2006. 05504.x
15. Yusuf S, Teo K, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59. http://dx.doi.org/10.1056/NEJMoa0801317 (Pubitemid 351522739)
16. Beckett NS, Peters R, Fletcher AE, et al., HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98. http://dx.doi.org/10.1056/NEJMoa0801369 (Pubitemid 351620109)
17. British Medical Association/NHS Employers. Quality and Outcomes Framework for 2012/13. Guidance for PCOs and practices. 2012. Available at http://www.nhsemployers.org/Aboutus/Publications/Documents/QOF-2012-13.pdf (accessed 2 December 2012).
18. Williams H (personal communication). National Institute for Health and Clinical Excellence. Summary of recommendations for the NICE menu and recommendations for retirement of indicators. August 2012. London: NICE, 2012. Available at http://www.nice.org.uk/media/1E3/79/ QOFACJune12SummaryRecommendations.pdf (accessed 1 December 2012).
19. NHS Information Centre. The Quality and Outcomes Framework. Available at http://www.ic.nhs.uk/statistics-and-data-collections/audits-and-performance/ the-quality-and-outcomes-framework (accessed 5th December 2012).
20. Health and Social Care Information Centre: Quality and Outcomes Framework 2011-12, practice level: clinical domain, hypertension data tables. Health and Social Care Information Centre 2012. Available from http://www.ic.nhs.uk/ article/2021/Website-Search?productid=9587&q=qof+data+2010%2f11&sort= Relevance&size=10&page=2&area= both#top (accessed 7 January 2013).
21. NHS Business Services Authority. NHS Prescription Services. Cardiovascular system national charts. NHS Business Services Authority, 2012. Available from http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/ PPDPrescribingAnalysisCharts/Cardio-National- Sep-2012.pdf (accessed 7 January 2013).
22. Van Wijk BL, Klungel OH, Heerdink ER, de Boer A. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005;23: 2101-7. http://dx.doi.org/10.1097/01.hjh.0000187261.40190.2e (Pubitemid 41830407)
23. Wald N, Law M, Morris J. Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. HTA 2003;7:1-94. Available from http://www.hta.ac.uk/execsumm/summ731.htm (accessed 7 January 2013).
24. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 trials. Am J Med 2009;122:290-300. http://dx.doi.org/10. 1016/j. amjmed.2008.09.038
25. Johnson A, Stafylas P, Stergiou GS. Effectiveness, safety and cost of drug substitution. Br J Clin Pharmacol 2010;70:321-34. http://dx.doi.org/10. 1111/j.1365-2125.2010.03681.x
26. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and offce blood pressure. Hypertension 2006;47:352-8. http://dx.doi.org/10.1161/01. HYP.0000203309.07140.d3 (Pubitemid 43740274)
27. Asmar R. Targeting blood pressure control with angiotensin receptor blockers. Int J Clin Pract 2006;60:315-20. http://dx.doi.org/10.1111/j.1368- 5031.2006.00784.x (Pubitemid 43337612)
28. Bakris GL, Sica D, Weber M, et al. The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure. J Clin Hypertens (Greenwich) 2011;13:81-8. http://dx.doi.org/10.1111/j.1751-7176.2010. 00425.x
29. Sica D, White WB, Weber MA et al. Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring. J Clin Hypertens (Greenwich) 2011;13:467-72. http://dx.doi.org/10. 1111/j.1751-7176.2011.00482.x
30. White WB, Weber Ma, Sica D, et al. Effects of the angiotensin receptor blocker azilasartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure monitoring in patients with stages 1 and 2 hypertension. Hypertension 2011;56:413-20. http://dx.doi.org/10.1161/HYPERTENSIONAHA.110. 163402
31. Caulfeld M, De Belder M, Cleveland T, et al. The Joint British Societies' consensus statement on renal denervation for resistance hypertension. January 2012. Available at http://www.bcs.com/documents/The-Joint-UK-Societies- Consensus- on-Renal-Denervation-for-resistant-hypertension. pdf (accessed 1 December 2012)
32. Myat A, Redwood SR, Qureshi AC, Spertus JA, Williams B. Resistant hypertension. BMJ 2012;345:e7473. http://dx.doi.org/10.1136/bmj.e7473
33. Tobe SW, Lewanczuk R. Resistant hypertension. Can J Cardiol 2009;25:315-17. http://dx.doi.org/10.1016/S0828-282X(09)70496-9
34. De la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8, 295 patients with resistant hypertension classifed on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57:898-902. http://dx.doi.org/10.1161/ HYPERTENSIONAHA.110.168948